December 15th, 2020
11 am to 12 pm EST
Advancing novel therapies into pre-clinical disease models for immunology and immuno-oncology research increases both complexity and cost. Additionally, the target population is humans and not widely used pre-clinical rodent species. In an ideal
drug discovery world, we would advance novel therapies straight into human testing and avoid the pre-clinical species. Obviously for both safety and cost reasons, that is not possible. However, as immunologists we are fortunate as we have
access to our target cells in the human blood. This webinar will focus on human in vitro immunology assays such as Tcell activation, phagocytosis, DC functions, Mixed Lymphocyte Reaction, and others that can be used in immunology
research. Additional, how human in vitro results can be used to design and implement better pre-clinical disease models.
Jeffery Cowden, PhD
Executive Director of Pharmacology
Jeffery is an experienced drug hunter with over 18 years of working experience at large pharmaceutical companies focusing on autoimmunity, allergy and cancer. He has published on the effects of novel drugs in RA, asthma and atopic dermatitis.
His work has contributed to 8 IND filings over his career.
Cost: No Cost!